Evidence map›Paper›PMID 23910079›Full record

ArticleCell stem cell2013

Transplantable liver organoids made from only three ingredients.

Holger Willenbring, Alejandro Soto-Gutierrez

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell stem cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Stem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver Injury.Journal of clinical and translational hepatology · 2014
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Holger WillenbringDepartment of Surgery, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, and Liver Center, University of California, San Francisco, San Francisco, CA 94143, USA. willenbringh@stemcell.ucsf.edu
Alejandro Soto-Gutierrez
University of California, San Francisco · USUniversity of Pittsburgh · US

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Modeling metabolic interactions of liver and fat with integrated microphysiological systemsUH3TR000487 · NCATS · UNIVERSITY OF CALIFORNIA BERKELEY · PI HEALY, KEVIN EDWARD · 2014 to 2016
$2.9M
Disease-Specific Integrated Microphysiological Human Tissue ModelsUH2TR000487 · NCATS · UNIVERSITY OF CALIFORNIA BERKELEY · PI HEALY, KEVIN EDWARD, LEE, LUKE P. · 2012 to 2013
$1.8M
Engineering of hepatic grafts with decellularized native matricesR00DK083556 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SOTO-GUTIERREZ, ALEJANDRO · 2011 to 2013
$707k
NCATS NIH HHS UH2 TR000487NCATS NIH HHS UH3 TR000487NIDDK NIH HHS P30 DK026743NIDDK NIH HHS P30 DK26743NIDDK NIH HHS R00 DK083556
6 · The paper itself

Abstract

Liver cell therapies using induced pluripotent stem cells (iPSCs) are in development. A recent paper in Nature by Takebe et al. expands the range of liver diseases that could be treated with iPSC-derived hepatocytes by combining them with endothelial and stromal cells to generate organoids that survive and function extrahepatically.

Indexed as

AnimalsHumansInduced Pluripotent Stem CellsLiverRegenerative Medicine

Identifiers

PMID23910079
PMCPMC3828077
OpenAlexW2014570133

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.